溃结安口服结肠定位胶囊初步药效学及制剂学研究
|
摘要
目的:我国UC的发病率近年呈上升趋势,已引起医药行业人士的广泛重视。“溃结安灌肠液”在新疆维吾尔医医院临床使用多年,对溃疡性结肠炎疗效显著,但该剂型应用不便,制约了药效发挥,结合UC的治疗需求,本课题旨在将其改为口服结肠靶向给药系统(OCTDS),以提高该药疗效和患者顺应性。方法:(1)首先进行了口服急性毒性试验的研究,为药效学、制剂学及后续工作提供剂量参考依据。随后,建立大鼠溃疡性结肠炎的模型动物,再分别给予溃结安(高、低剂量组),以柳氮磺吡啶肠溶片为阳性对照,观察各组大鼠结肠形态学变化,通过结肠组织损伤评分、测定肠重指数、免疫器官相对重量、大鼠血清中炎性细胞因子MPO、SOD活性及病理切片来观察该药的初步药效。(2)通过对制剂成型工艺、临界相对湿度考察、胶囊包衣处方三方面的研究,制备溃结安pH依赖型和pH依赖-时滞型结肠靶向包衣胶囊。为评价该制剂,建立了游离没食子酸的HPLC含量测定方法,以此为指标进行体外溶出实验,并且以硫酸钡造影技术观察犬口服该制剂后的体内释放情况。结果:(1)小鼠对溃结安的最大耐受倍数为人的833倍。溃结安低剂量组的治疗作用与阳性药组有差异,溃结安高剂量组与其无显著差异。(2)通过将药物制粒后,灌装于胶囊再包衣的工艺路线可得到pH依赖型和pH依赖-时滞型结肠靶向包衣胶囊,前者工艺相对简单,可操作性强。该胶囊在人工胃液、人工肠液几乎不释放,在人工结肠液中1h累积释放达到104%。犬消化道X射线照片清晰可见该胶囊在犬的结肠部位释放。结论:(1)没食子提取物毒性小,安全系数大,口服该药对TNBS所致UC大鼠有明确的治疗作用。(2)通过胶囊包衣制备得到的pH依赖型结肠靶向胶囊在体内外均有较好的释药性能。(3)该制剂工艺的研究,合理可行,在改进传统临床治疗UC给药方式的同时推动了中药、民族药制剂研究水平的提高。
Object: In recent years ,disease incidence of UC is upgrading in China,this arise high attention of many from medicine vocation. Kuijiean enema was used many years in Xinjiang Uighur hospital,which has conspicuous clinical effect. But this dosage form is inconvenience and restricted in application,so we change it into OCTDS in order to raise its therapeutics effect and lessen the patient’s painful. Methods: 1)First of all,we progressed acute noxious experiment for oral use,which provided reference evidence for pharmacodynamics and galenic pharmacy. In this base on,a rat model of UC was induced by TNBS/ethanol in order to evaluate the effects of KJA. The microscopically and microscopically examination of the colon was detected. The immune organic relative weights were menstruated to imply the change of immune functions in rats. The activity of SOD and MPO were detected. 2)During the study of form selecting,forming and coating artwork, pH depended type colon target preparations of KJA and pH depended-time lagged type ones were acquired.AHPLC method was established in vitro dissolution determination for preparations. And the releasing site and time of the drugs from the colon-specific coated capsule in dogs were screened by X scintigraphy. Results: 1)The maximum tolerated doseof mouse is 833 times than that of man. The high doge group of KJA has appositive therapeutic effect to UC. 2)The molding techniques of pH depended type colon target preparations of KJA and pH depended-time lagged type ones were researched. The former is more simply and operability.At last,the results of authentication show that KJA colon-specific coated capsule had the colon targeting characteristics in vitro and vivo. Conclusion: This research identified Turkish galls medicinal have a small noxious and obviously therapeutic effect by oral. Exploitation of this medicine not only changed traditional administration mode for UC and elevated the level of Chinese ethical medicine’s research.
Object: In recent years ,disease incidence of UC is upgrading in China,this arise high attention of many from medicine vocation. Kuijiean enema was used many years in Xinjiang Uighur hospital,which has conspicuous clinical effect. But this dosage form is inconvenience and restricted in application,so we change it into OCTDS in order to raise its therapeutics effect and lessen the patient’s painful. Methods: 1)First of all,we progressed acute noxious experiment for oral use,which provided reference evidence for pharmacodynamics and galenic pharmacy. In this base on,a rat model of UC was induced by TNBS/ethanol in order to evaluate the effects of KJA. The microscopically and microscopically examination of the colon was detected. The immune organic relative weights were menstruated to imply the change of immune functions in rats. The activity of SOD and MPO were detected. 2)During the study of form selecting,forming and coating artwork, pH depended type colon target preparations of KJA and pH depended-time lagged type ones were acquired.AHPLC method was established in vitro dissolution determination for preparations. And the releasing site and time of the drugs from the colon-specific coated capsule in dogs were screened by X scintigraphy. Results: 1)The maximum tolerated doseof mouse is 833 times than that of man. The high doge group of KJA has appositive therapeutic effect to UC. 2)The molding techniques of pH depended type colon target preparations of KJA and pH depended-time lagged type ones were researched. The former is more simply and operability.At last,the results of authentication show that KJA colon-specific coated capsule had the colon targeting characteristics in vitro and vivo. Conclusion: This research identified Turkish galls medicinal have a small noxious and obviously therapeutic effect by oral. Exploitation of this medicine not only changed traditional administration mode for UC and elevated the level of Chinese ethical medicine’s research.
引文
[1] Xu CT,Meng SY,Pan BR.Drug therapy for ulcerative colitis . [J] World J Gastroenterol,2004,10(16):2311-2317
[2]许昌泰,潘伯荣,郭学刚.炎症性肠病研究现状[J]天津医药,2002,30(6):382-384
[3] Klotz U,Schwab M. Topical delivery of therapeutic agents in the treatment of Inflammatory bowel disease. [J] Advanced Drug Delivery Reviews,2005,57: 267-279
[4] Katz J.成人炎症性肠病的治疗[J]Chin J Gastroenterol,2007,12(2): 106- 113
[5]胡鸿毅.中药防治溃疡性结肠炎的临床和机理研究概况[J]上海中医药杂志,2004,38(3):-60-62
[6]王正忠.中药灌肠治疗溃疡性结肠炎近况[J]中医外治杂志.2003,12(2):-40-41
[7]刘卫华.谈中药鞣质成分在临床中的应用[J]黑龙江中医药2005(4):55
[8]陆彬主编.药物新剂型与新技术[M].北京:人民卫生出版社,1998:281-282
[9] Rodriguez M,Vila-jato JL,Torres D.Design of a new multipaticulate system for potential site-specific and controlled drug delivery to the colonic region.J Controlled release,[J]1998,55(1):67
[10] NUGENT S G,KUMAR D,RAMPTON D S,et al.Intestinal luminal pH in inflammatory bowel disease:possible determinants and implications of therapy with aminosalicylates and other drugs[J].Gut,2001,48:571-577
[11]赵建,张钧寿,张瑛等.胰岛素微乳大鼠结肠给药的药效学研究[J]中国医科大学学报,2004,35(6):491
[12]郭晓冬.加味四逆散治疗大鼠溃疡性结肠炎的分子机制研究.[D]学位论文,2004,北京中医药大学
[13] Zhang HH,Kumar S,Barnett AH,et al. Ceiling cultured of mature human adlpocytes: use in studies of adipocyte functions[J]. J Endocrin.,2000,164 (1): 119-128
[14]刘新宇,邸琳.慢结灵胶囊治疗大鼠溃疡性结肠炎的药效学研究[J]中国实验方剂学杂志,2006,12(2)46-51
[15]赵海梅,刘端勇.芪仙汤治疗大鼠溃疡性结肠炎的药效学机制探讨[J]中国中医基础医学杂志,2007,13(3)203-206
[16] Lin WT,Zhu P.Practical Clinical Immunology [M].The Fourth Military Med Press,2003.19
[17]郑红斌,胡鸿毅,陆雄等.清肠栓对溃疡性结肠炎防治作用的动物实验研究.[J]上海中医药大学学报,2000,14(4):54-56
[18]朱昌全,何为胜.葛根芩连有效部位抗溃疡性结肠炎的相关药效学研究[J]湖南中医药大学学报,2007,27(1):28-30
[19]陈诗仁.愈结宁对实验性大鼠溃疡性结肠炎抗炎、镇痛作用研究[J]广东药学院学报,2002,18(3):214-217
[20]郑礼,高振强,王淑仙.大鼠溃疡性结肠炎模型的实验研究[J]中国药理学通报,1998,14(4):370-372
[21]陈重.口服结肠靶向给药系统的研究现状[J]中国药业.2002,11(2):76-77
[22]张钧寿.结肠靶向给药系统研究进展[J]中国新药杂志.1999,8(6):368-371
[23]张立超,胡晋红,连桂芳,等.丙烯酸树脂在薄膜包衣中的应用[J]中国医院药学杂志.2001,21(5):301-302
[24]谢兴亮.愈肠宁口服结肠靶向制剂的药学研究[D].学位论文,2005,成都中医药大学
[25]徐彦,齐宪荣.5-氨基水杨酸结肠定位给药pH与时间同时控制小丸的制备与体外释放[J].中国新药杂志,2004,13;129-133
[26] Muraokea M,Hu Z,Shimokawa T,et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. [J] Controlled Release,1998,52(1/2):119-129
[27] Frieri G,Pimpo MT,Palumbo G,et al.Anastomotic configuration and mucosal 5-aminosalicylic acid (5-ASA)concentrations in patients with Crohn‘s disease:a GISC study[J].Am j Gastroenteral,2000,95(6):1486.
[28] Ishibashi T,Pitcairn GR,Yoshino H,et al. Dcintigraphic evaluation of a new capsule-type colon specific drug delivery system in health volunteers.[J] Phar Sci,1998,87(5):531
[29]李妍,李宏建,苏乐群等.4-氨基水杨酸钠结肠定位包衣片的制备与体外释放[J]中国医院药学杂志.2006,26(4):402-405
[30]张宣,吴芳,张志荣. 5-氨基水杨酸结肠定位释药包衣片在狗体内的靶向性研究. [J]中国现代应用药学杂志,2003,20(4): 288.
[31]沈熊,吴伟.徐惠南.口服结肠定位释药系统评价方法[J]中国临床药学杂志,2004, 13(4):250-253
[32]邱雪兰,杨明等.康复新结肠靶向胶囊的体内外评价[J]中国中药杂志,2007, 32(16):1644-1647
[33] M Turkoglu,T Ugurlu In vitro evaluation of pectim-HPMC Compressioncoated-aminosalicylic acid tablets for colonic delivery [J].Eur pham Biopharm,2002,53(1):65
[34] Clear NJ,Milton A,Humphrey M,et al .Evaluation of the intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon [J].Eur J Pham Sci,2001,13(4):375
[35]柴春彦,刘国艳,李文范.犬消化道X线造影检查.中国兽医学报,1999(5)483-485
[36]李春云,张宣,张志荣等.99-Tc-m-5-氨基水杨酸包衣片在结肠的定位释药[J].同位素,2004,17(1)8-10
[37] Krishnaiah Ysr,Satyanarayana S,Rama-prasad YU,et al Evaluation of Guar Gum as a compression Coat for Drug Targeting to colon [J],Int J Pham,1998,171(2): 137-146
[38]陈英群,马贵同.细胞因子与溃疡性结肠炎相关性研究进展[J]中国中西医结合消化杂志,2003,11(1 ):57-59
[39]锁堂,吴焕金,施达仁.白介素与溃疡性结肠炎[J]世界华人消化杂志,2006,14(4): 405-411
[40]卢艺涛,高静,姚桂琴.溃疡性结肠炎患者相关细胞因子的实验性研究[J]现代预防医学,2005,32(7):735-736
[41] Vainer B,Nielsen O,Hendel J,et al. Colonic expression and synthesis of interleukin 13and interleukin 15 in inflammatory bowel disease.Cytokine,2000,12:1531-1536
[42]刘井波,彭双清.脂质过氧化作用与线粒体损伤[J]中国预防医学杂志,2005,6(2): 167-170
[43]葛贺,孙丕东.TNFα和SOD在溃疡性结肠炎发病中活性变化的实验探究[J]临床医学,2007,20(1):160-162
[44]王晓兰,吕和平,康跃军.肿瘤坏死因子α与炎症性肠病研究进展[J].洛阳医专学报,2002,20(3):264-265
[45]崔淑兰,祝斌,梁坚.溃疡性结肠炎病人血清中TNF–α的变化及其临床意义[J],当代医师杂志,1998,3(8):13-14
[46]徐萍;徐东升;陈江等.髓过氧化物酶对炎症性肠病病情活动监测的临床价值[J]实用临床医学,2006,7(12):34-37
[47] Iwakura T ,Ishigame H .The IL-23/IL-17 axis in inflammation. The Journal of Clinical Investigation,2006,116(5):1218-1222
[48] Menchen L,Colon AL,Madrigal JL,et al. Activity of inducible and neuronal nitric oxide synthases in colonic mucosa predicts progression of ulcerative colitis. Am J Gastroenterol,2004,99 (9): 1756-1764.
[49] Wei NH ,Lu B,Preparation,morphology and in vitro release of chitosan coated liposomes of fluorouracil for colon targeting [J]. Acta Pharm Sci(药学学报),2003,38(1):53-56
[50] NUGENT S G,KUMAR D,RAMPTON D S,et al.Intestinal luminal pH in inflammatory bowel disease:possible determinants and implications of therapy with aminosalicylates and other drugs[J].Gut,2001,48:571-577
[51]杜佳丽,谭丰苹,朱德全,等5-氟尿嘧啶结肠定位释药微囊的制备与释药特性[J]清华大学学报,2005,45(12):1657
[52]刘洪英,郑小林,皮喜田,等.消化道定位药物释放技术及其在新药开发中的应用[J]中国药学杂志,2005,40(13):970
[53]李国锋,陈建海,陈志良.结肠定位给药技术研究进展[J]中国药房,2005,16(1): 64-66
[54]任飞亮,裴元英.口服结肠定位释药系统的研究进展.[J]中国药学杂志,2005;40: 1290-1291
[55]徐勤.鞣质的研究进展.[J]华夏医学2004,17(1):113
[56]闫滨,张秋红,刘秀芳.植物中鞣质类化合物的化学研究进展[J]山东医药工业2003,22(1):34
[57] Liao XP,Lu ZB,Shi B Slective adsoption of vegetable of tannins onto collagen fibres. [J] Ind Eng Chem Res,2003,42:3397
[58]刘延泽,王彩芳,韩全斌等.柳兰化学成分研究Ⅱ鞣质及多酚类化合物[J].中草药,2003,34(11):967
[59]石碧,狄莹著.植物多酚[M].北京:科学出版社.2000,19
[60]刘卫华.谈中药鞣质成分在临床中的应用[J]黑龙江中医药2005(4):55
[61]闫滨,张秋红,刘秀芳.植物中鞣质类化合物的化学研究进展[J]山东医药工业2003,22(1):34
[62]胡小刚,李继革,郭书好.鞣质分析研究进展.[J]新疆中医药,2001,19(3):78
[63]王立,金哲雄.平嗪鞣质成分研究[J]中草药2006 37(6):810
[64] Jin Z X,Wang L.Studies on components from the leaves of Corylus heterophylla[J].Chin Tradit Herb Drugs(中草药).2004,35(9):606
[65] Zhang LZ,Guo Yj,Tu GZ,et al.Islation and Identiyiciation of novel polyphenolic compound from phyllanthus urinaria L.[J].J Chin Med Mater(中药材)2000,5(12):724
[66] Zhang YG Abe T.Tanaka T.et al phyllanemblinins A F. new ellagitinnains from phyllanthus emblica [J].J Nat Prod ,2001,64:1527
[67] Liao XP,Lu ZB,Shi B Slective adsoption of vegetable of tannins onto collagen fibres. Ind Eng Chem Res,2003,42:3397
[68]张立超,胡晋红,连桂芳等.丙烯酸树脂在薄膜包衣中的应用[J]中国医院药学杂志.2001,21(5):301-302
[69]张立超,胡晋红,李珍等.渗透型丙烯酸树脂包衣控制膜中增塑剂的优选[J]药学学报,2001,36(12):93-94
[70]张立超,胡晋红,连桂芳等.两种增塑剂的用量对控释包衣膜力学和药物渗透性能的影响[J]第二军医大学学报.2002,23(5):579-580
[71]国家食品药品监督管理局.药品注册管理办法.2005,47
[72]徐莲英,候世祥.[M]中药制药工艺技术解析.人民卫生出版社,155,156,158,162
[73]闫惠俊,龙致贤,王玉蓉等.肠安康微丸结肠靶向验证实验[J]中成药,2003,25(7): 523-526
[74]程刚,肖云彩,吴寿荣等.新型茶碱口服结肠靶向给药系统的体内动力学[J]沈阳药科大学学报.2003,20(1):1-4
[75]奇美玲,吴德政.结肠给药系统的设计及体内评价. [J]中国临床药理学杂志,2000,16 (2):150
[76]刘洪英,郑小林,皮喜田,等.消化道定位药物释放技术及其在新药开发中的应用. [J]中国药学杂志,2005,40(13):970
[77]张瑜,侯世祥,陈钢,等.魔芋胶为载体的结肠定位给药系统体外释放介质研究. [J]中国药学杂志,2006,4(41):604-607
[78]赵明,熊燃等.对口服结肠定位给药系统的认识及审评实践. [J]中国临床药理学杂志,2006,22(6):475-478
[79] Sinha VR,Kumria R Polysaccharides in colon-specific drug delivery [J].Int J of pharmaceut,2001;224:19-38
[80] Mooter GVD,Maris B,samyn C,etal. Use of azo polymers for colon-specific drug delivery [J] Pham Sci,1997:86:1312
[1]陆彬主编.药物新剂型与新技术[M].北京:人民卫生出版社,1998:281-282
[2]郑芝田主编.胃肠病学[M].北京:人民卫生出版社,1986:440
[3] Rodriguez M,Vila-jato JL,Torres D.Design of a new multipaticulate system for potential site-specific and controlled drug delivery to the colonic region.J Controlled release,1998,55(1):67
[4]平其能.现代药剂学[M].北京:中国医药科技出版社,1998.
[5]张纪兴,陈一岳,程国华,等.甲硝唑微囊口服结肠定位给药系统的制备[J].中国医院药学杂志,2003,23(7):409
[6]杜佳丽,谭丰苹,朱德全,等5-氟尿嘧啶结肠定位释药微囊的制备与释药特性[J].清华大学学报,2005,45(12):1657
[7] WATTS P J,ILLUM L. Colonic drug delivery[J]. Drug Dev Ind Pharm,1997,23(9): 893-913
[8]齐美玲,王鹏,吴德孜.替硝唑结肠给药系统的研制[J].中国医药工业杂志,2003, 34(34):172
[9] Muraokea M,Hu Z,Shimokawa T,et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers.J Controlled Release,1998,52(1/2):119-129
[10] Muraokea M,Kimura G,Zhaopeng H,et al. Ulcerative colitis-colon delivery of 5-aminosalicylic carriers to the inflamed colonic mucosa [J]. Nippon Rinsho,1998, 56(3):788
[11] Zoe W,John F,David A,et al. Studies on amidated pectins as potential carriers in colonic drug delivery [J]. J Pharm Pharmacol,1997,49(4):622-625
[12] KaKoulide EP,Smart JD,Tsibauklis J.Azocrosslinked poly for colonic delivery and adhesion specificity. In vitro degradation and preliminary ex vivo bioadhesion studies [J]. J Controlled Release,1998,54(2):95-109
[13] Mooter GVD,Maris B,Samyn C,et al .Use of azo-polymers for colon-specific drug delivery [J]. J Pharm Sci,1997,86(12):1312-1318
[14] Wei NH ,Lu B,Preparation,morphology and in vitro release of chitosan coated liposomes of fluorouracil for colon targeting [J]. Acta Pharm Sci(药学学报),2003,38(1):53-56
[15]张瑜,侯世祥,陈钢,等.魔芋胶为载体的结肠定位给药系统体外释放介质研究[J].中国药学杂志,2006,4(41):604-607
[16] Ishibashi T,Pitcairn GR,Yoshino H,et al. Dcintigraphic evaluation of a new capsule-type colon specific drug delivery system in health volunteers.J Pharm Sci,1998,87(5):531
[17]李妍,李宏建,苏乐群等.4-氨基水杨酸钠结肠定位包衣片的制备与体外释放[J].中国医院药学杂志.2006,26(4):402-405
[18] NUGENT S G,KUMAR D,RAMPTON D S,et al.Intestinal luminal pH in inflammatory bowel disease:possible determinants and implications of therapy with aminosalicylates and other drugs[J].Gut,2001,48:571-577
[19]齐美玲,吴德政.结肠给药系统的设计及体内评价[J].中国临床药理杂志,2000, 16(2):150
[20] De Vos M,Verdievel H,Schoonjans R,et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparation[J].Gut,1992,33(10):1338.
[21] Frieri G,Pimpo MT,Palumbo G,et al.Anastomotic configuration and mucosal 5-aminosalicylic acid (5-ASA)concentrations in patients with Crohn‘s disease:a GISC study[J].Am j Gastroenteral,2000,95(6):1486.
[22]赵建,张钧寿,张瑛等.胰岛素微乳大鼠结肠给药的药效学研究[J].中国医科大学学报,2004,35(6):491
[23]刘洪英,郑小林,皮喜田,等.消化道定位药物释放技术及其在新药开发中的应用[J].中国药学杂志,2005,40(13):970
[1]葛贺,孙丕东.TNFα和SOD在溃疡性结肠炎发病中活性变化的实验探究[J].临床医学,2007,20(1):160-162
[2]陆立,周燕,王焕明等.肿瘤坏死因子与炎症性肠病[J].国外医学·消化系统疾病分册,1998,18(1):9-11
[3]杜学良,孙瑛,栾亮. TNF增加培养的内皮细胞与血小板粘附及其机制[J].中国病理生理杂志,1997,13(5):470-473
[4]王晓兰,吕和平,康跃军.肿瘤坏死因子α与炎症性肠病研究进展[J].洛阳医专学报,2002,20(3):264-265
[5]崔淑兰,祝斌,梁坚.溃疡性结肠炎病人血清中TNF–α的变化及其临床意义[J],当代医师杂志,1998,3(8):13-14
[6]锁堂,吴焕金,施达仁.白介素与溃疡性结肠炎[J].世界华人消化杂志,2006,14(4): 405-411
[7]古学文.溃疡性结肠炎患者血清中IL-2及sIL-2浓度变化的研究[J].临床和实验医学杂志,2003,2:153-158
[8]卢艺涛,高静,姚桂琴.溃疡性结肠炎患者相关细胞因子的实验性研究[J].现代预防医学,2005,32(7):735-736
[9]陈英群,马贵同.细胞因子与溃疡性结肠炎相关性研究进展[J].中国中西医结合消化杂志,2003,11(1 ):57-59
[10]李艳颖,陈津生.IL监测溃疡性结肠炎病情变化的研究进展[J].天津医科大学学报,2006,12(4):597-599
[11] Vainer B,Nielsen O,Hendel J,et al. Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease[J].Cytokine ,2000,12: 1531-1536
[12] Iwakura T ,Ishigame H .The IL-23/IL-17 axis in inflammation[J]. The Journal of Clinical Investigation,2006,116(5):1218-1222
[13]梁雄均,马泽,曾雅静.白介素4和17在溃疡性结肠炎发生发展中的作用[J].右江医学,2005,33(1):6-8
[14]张玲英,杨明清,游自立等.溃疡性结肠炎患者血清IL-18的变化及意义[J].现代中西医结合杂志,2002,11:586-589
[15]张维,赵志泉,刘平等.IL8、TNF–α在Hp感染中作用的研究[J].胃肠病学和肝病学杂志,2000,9:270-273
[16]刘井波,彭双清.脂质过氧化作用与线粒体损伤[J].中国预防医学杂志,2005,6(2): 167-170
[17] Koutrobakis I.E.et al.DIG[J].DIS.SCI.2004,49(9):1433-1437
[18]汤学民,李毓琦,何俊.尿中脂质过氧化物测定方法的探讨[J].广西医学,2003, 25(4):515-518
[19] Mulden TPJ ,et al. Decrease in two intestinal copper/zinc containing proteins with antioxidant function in inflammatory bowel disease[J]. Gut,1991,32 (10)∶1 146
[20] Menchen L,Colon AL,Madrigal JL,et al. Activity of inducible and neuronal nitric oxide synthases in colonic mucosa predicts progression of ulcerative colitis[J]. Am J Gastroenterol,2004,99 (9): 1756-1764.
[21]陈垦,汤斌,祝斌.溃疡性结肠炎患者血清一氧化氮检测及意义[J].中国医师杂志,2002,4(10):1073-1075
[22]魏艳静,卞红磊,武会珍.溃疡性结肠炎患者体内血小板功能状态研究[J].临床医学,2003,18(11):608-609
[23]施嫣红,黄培新,郭传勇.溃疡性结肠炎患者血小板功能的临床研究[J].同济大学学报(医学版),2006,27(2):48-50
[24]倪伟虹,杨英,陈隆典.活动性炎症性肠病与血小板参数的相关性及其临床意义[J].中国医师进修杂志(内科版),2006,29(12):25-27
[2]许昌泰,潘伯荣,郭学刚.炎症性肠病研究现状[J]天津医药,2002,30(6):382-384
[3] Klotz U,Schwab M. Topical delivery of therapeutic agents in the treatment of Inflammatory bowel disease. [J] Advanced Drug Delivery Reviews,2005,57: 267-279
[4] Katz J.成人炎症性肠病的治疗[J]Chin J Gastroenterol,2007,12(2): 106- 113
[5]胡鸿毅.中药防治溃疡性结肠炎的临床和机理研究概况[J]上海中医药杂志,2004,38(3):-60-62
[6]王正忠.中药灌肠治疗溃疡性结肠炎近况[J]中医外治杂志.2003,12(2):-40-41
[7]刘卫华.谈中药鞣质成分在临床中的应用[J]黑龙江中医药2005(4):55
[8]陆彬主编.药物新剂型与新技术[M].北京:人民卫生出版社,1998:281-282
[9] Rodriguez M,Vila-jato JL,Torres D.Design of a new multipaticulate system for potential site-specific and controlled drug delivery to the colonic region.J Controlled release,[J]1998,55(1):67
[10] NUGENT S G,KUMAR D,RAMPTON D S,et al.Intestinal luminal pH in inflammatory bowel disease:possible determinants and implications of therapy with aminosalicylates and other drugs[J].Gut,2001,48:571-577
[11]赵建,张钧寿,张瑛等.胰岛素微乳大鼠结肠给药的药效学研究[J]中国医科大学学报,2004,35(6):491
[12]郭晓冬.加味四逆散治疗大鼠溃疡性结肠炎的分子机制研究.[D]学位论文,2004,北京中医药大学
[13] Zhang HH,Kumar S,Barnett AH,et al. Ceiling cultured of mature human adlpocytes: use in studies of adipocyte functions[J]. J Endocrin.,2000,164 (1): 119-128
[14]刘新宇,邸琳.慢结灵胶囊治疗大鼠溃疡性结肠炎的药效学研究[J]中国实验方剂学杂志,2006,12(2)46-51
[15]赵海梅,刘端勇.芪仙汤治疗大鼠溃疡性结肠炎的药效学机制探讨[J]中国中医基础医学杂志,2007,13(3)203-206
[16] Lin WT,Zhu P.Practical Clinical Immunology [M].The Fourth Military Med Press,2003.19
[17]郑红斌,胡鸿毅,陆雄等.清肠栓对溃疡性结肠炎防治作用的动物实验研究.[J]上海中医药大学学报,2000,14(4):54-56
[18]朱昌全,何为胜.葛根芩连有效部位抗溃疡性结肠炎的相关药效学研究[J]湖南中医药大学学报,2007,27(1):28-30
[19]陈诗仁.愈结宁对实验性大鼠溃疡性结肠炎抗炎、镇痛作用研究[J]广东药学院学报,2002,18(3):214-217
[20]郑礼,高振强,王淑仙.大鼠溃疡性结肠炎模型的实验研究[J]中国药理学通报,1998,14(4):370-372
[21]陈重.口服结肠靶向给药系统的研究现状[J]中国药业.2002,11(2):76-77
[22]张钧寿.结肠靶向给药系统研究进展[J]中国新药杂志.1999,8(6):368-371
[23]张立超,胡晋红,连桂芳,等.丙烯酸树脂在薄膜包衣中的应用[J]中国医院药学杂志.2001,21(5):301-302
[24]谢兴亮.愈肠宁口服结肠靶向制剂的药学研究[D].学位论文,2005,成都中医药大学
[25]徐彦,齐宪荣.5-氨基水杨酸结肠定位给药pH与时间同时控制小丸的制备与体外释放[J].中国新药杂志,2004,13;129-133
[26] Muraokea M,Hu Z,Shimokawa T,et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. [J] Controlled Release,1998,52(1/2):119-129
[27] Frieri G,Pimpo MT,Palumbo G,et al.Anastomotic configuration and mucosal 5-aminosalicylic acid (5-ASA)concentrations in patients with Crohn‘s disease:a GISC study[J].Am j Gastroenteral,2000,95(6):1486.
[28] Ishibashi T,Pitcairn GR,Yoshino H,et al. Dcintigraphic evaluation of a new capsule-type colon specific drug delivery system in health volunteers.[J] Phar Sci,1998,87(5):531
[29]李妍,李宏建,苏乐群等.4-氨基水杨酸钠结肠定位包衣片的制备与体外释放[J]中国医院药学杂志.2006,26(4):402-405
[30]张宣,吴芳,张志荣. 5-氨基水杨酸结肠定位释药包衣片在狗体内的靶向性研究. [J]中国现代应用药学杂志,2003,20(4): 288.
[31]沈熊,吴伟.徐惠南.口服结肠定位释药系统评价方法[J]中国临床药学杂志,2004, 13(4):250-253
[32]邱雪兰,杨明等.康复新结肠靶向胶囊的体内外评价[J]中国中药杂志,2007, 32(16):1644-1647
[33] M Turkoglu,T Ugurlu In vitro evaluation of pectim-HPMC Compressioncoated-aminosalicylic acid tablets for colonic delivery [J].Eur pham Biopharm,2002,53(1):65
[34] Clear NJ,Milton A,Humphrey M,et al .Evaluation of the intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon [J].Eur J Pham Sci,2001,13(4):375
[35]柴春彦,刘国艳,李文范.犬消化道X线造影检查.中国兽医学报,1999(5)483-485
[36]李春云,张宣,张志荣等.99-Tc-m-5-氨基水杨酸包衣片在结肠的定位释药[J].同位素,2004,17(1)8-10
[37] Krishnaiah Ysr,Satyanarayana S,Rama-prasad YU,et al Evaluation of Guar Gum as a compression Coat for Drug Targeting to colon [J],Int J Pham,1998,171(2): 137-146
[38]陈英群,马贵同.细胞因子与溃疡性结肠炎相关性研究进展[J]中国中西医结合消化杂志,2003,11(1 ):57-59
[39]锁堂,吴焕金,施达仁.白介素与溃疡性结肠炎[J]世界华人消化杂志,2006,14(4): 405-411
[40]卢艺涛,高静,姚桂琴.溃疡性结肠炎患者相关细胞因子的实验性研究[J]现代预防医学,2005,32(7):735-736
[41] Vainer B,Nielsen O,Hendel J,et al. Colonic expression and synthesis of interleukin 13and interleukin 15 in inflammatory bowel disease.Cytokine,2000,12:1531-1536
[42]刘井波,彭双清.脂质过氧化作用与线粒体损伤[J]中国预防医学杂志,2005,6(2): 167-170
[43]葛贺,孙丕东.TNFα和SOD在溃疡性结肠炎发病中活性变化的实验探究[J]临床医学,2007,20(1):160-162
[44]王晓兰,吕和平,康跃军.肿瘤坏死因子α与炎症性肠病研究进展[J].洛阳医专学报,2002,20(3):264-265
[45]崔淑兰,祝斌,梁坚.溃疡性结肠炎病人血清中TNF–α的变化及其临床意义[J],当代医师杂志,1998,3(8):13-14
[46]徐萍;徐东升;陈江等.髓过氧化物酶对炎症性肠病病情活动监测的临床价值[J]实用临床医学,2006,7(12):34-37
[47] Iwakura T ,Ishigame H .The IL-23/IL-17 axis in inflammation. The Journal of Clinical Investigation,2006,116(5):1218-1222
[48] Menchen L,Colon AL,Madrigal JL,et al. Activity of inducible and neuronal nitric oxide synthases in colonic mucosa predicts progression of ulcerative colitis. Am J Gastroenterol,2004,99 (9): 1756-1764.
[49] Wei NH ,Lu B,Preparation,morphology and in vitro release of chitosan coated liposomes of fluorouracil for colon targeting [J]. Acta Pharm Sci(药学学报),2003,38(1):53-56
[50] NUGENT S G,KUMAR D,RAMPTON D S,et al.Intestinal luminal pH in inflammatory bowel disease:possible determinants and implications of therapy with aminosalicylates and other drugs[J].Gut,2001,48:571-577
[51]杜佳丽,谭丰苹,朱德全,等5-氟尿嘧啶结肠定位释药微囊的制备与释药特性[J]清华大学学报,2005,45(12):1657
[52]刘洪英,郑小林,皮喜田,等.消化道定位药物释放技术及其在新药开发中的应用[J]中国药学杂志,2005,40(13):970
[53]李国锋,陈建海,陈志良.结肠定位给药技术研究进展[J]中国药房,2005,16(1): 64-66
[54]任飞亮,裴元英.口服结肠定位释药系统的研究进展.[J]中国药学杂志,2005;40: 1290-1291
[55]徐勤.鞣质的研究进展.[J]华夏医学2004,17(1):113
[56]闫滨,张秋红,刘秀芳.植物中鞣质类化合物的化学研究进展[J]山东医药工业2003,22(1):34
[57] Liao XP,Lu ZB,Shi B Slective adsoption of vegetable of tannins onto collagen fibres. [J] Ind Eng Chem Res,2003,42:3397
[58]刘延泽,王彩芳,韩全斌等.柳兰化学成分研究Ⅱ鞣质及多酚类化合物[J].中草药,2003,34(11):967
[59]石碧,狄莹著.植物多酚[M].北京:科学出版社.2000,19
[60]刘卫华.谈中药鞣质成分在临床中的应用[J]黑龙江中医药2005(4):55
[61]闫滨,张秋红,刘秀芳.植物中鞣质类化合物的化学研究进展[J]山东医药工业2003,22(1):34
[62]胡小刚,李继革,郭书好.鞣质分析研究进展.[J]新疆中医药,2001,19(3):78
[63]王立,金哲雄.平嗪鞣质成分研究[J]中草药2006 37(6):810
[64] Jin Z X,Wang L.Studies on components from the leaves of Corylus heterophylla[J].Chin Tradit Herb Drugs(中草药).2004,35(9):606
[65] Zhang LZ,Guo Yj,Tu GZ,et al.Islation and Identiyiciation of novel polyphenolic compound from phyllanthus urinaria L.[J].J Chin Med Mater(中药材)2000,5(12):724
[66] Zhang YG Abe T.Tanaka T.et al phyllanemblinins A F. new ellagitinnains from phyllanthus emblica [J].J Nat Prod ,2001,64:1527
[67] Liao XP,Lu ZB,Shi B Slective adsoption of vegetable of tannins onto collagen fibres. Ind Eng Chem Res,2003,42:3397
[68]张立超,胡晋红,连桂芳等.丙烯酸树脂在薄膜包衣中的应用[J]中国医院药学杂志.2001,21(5):301-302
[69]张立超,胡晋红,李珍等.渗透型丙烯酸树脂包衣控制膜中增塑剂的优选[J]药学学报,2001,36(12):93-94
[70]张立超,胡晋红,连桂芳等.两种增塑剂的用量对控释包衣膜力学和药物渗透性能的影响[J]第二军医大学学报.2002,23(5):579-580
[71]国家食品药品监督管理局.药品注册管理办法.2005,47
[72]徐莲英,候世祥.[M]中药制药工艺技术解析.人民卫生出版社,155,156,158,162
[73]闫惠俊,龙致贤,王玉蓉等.肠安康微丸结肠靶向验证实验[J]中成药,2003,25(7): 523-526
[74]程刚,肖云彩,吴寿荣等.新型茶碱口服结肠靶向给药系统的体内动力学[J]沈阳药科大学学报.2003,20(1):1-4
[75]奇美玲,吴德政.结肠给药系统的设计及体内评价. [J]中国临床药理学杂志,2000,16 (2):150
[76]刘洪英,郑小林,皮喜田,等.消化道定位药物释放技术及其在新药开发中的应用. [J]中国药学杂志,2005,40(13):970
[77]张瑜,侯世祥,陈钢,等.魔芋胶为载体的结肠定位给药系统体外释放介质研究. [J]中国药学杂志,2006,4(41):604-607
[78]赵明,熊燃等.对口服结肠定位给药系统的认识及审评实践. [J]中国临床药理学杂志,2006,22(6):475-478
[79] Sinha VR,Kumria R Polysaccharides in colon-specific drug delivery [J].Int J of pharmaceut,2001;224:19-38
[80] Mooter GVD,Maris B,samyn C,etal. Use of azo polymers for colon-specific drug delivery [J] Pham Sci,1997:86:1312
[1]陆彬主编.药物新剂型与新技术[M].北京:人民卫生出版社,1998:281-282
[2]郑芝田主编.胃肠病学[M].北京:人民卫生出版社,1986:440
[3] Rodriguez M,Vila-jato JL,Torres D.Design of a new multipaticulate system for potential site-specific and controlled drug delivery to the colonic region.J Controlled release,1998,55(1):67
[4]平其能.现代药剂学[M].北京:中国医药科技出版社,1998.
[5]张纪兴,陈一岳,程国华,等.甲硝唑微囊口服结肠定位给药系统的制备[J].中国医院药学杂志,2003,23(7):409
[6]杜佳丽,谭丰苹,朱德全,等5-氟尿嘧啶结肠定位释药微囊的制备与释药特性[J].清华大学学报,2005,45(12):1657
[7] WATTS P J,ILLUM L. Colonic drug delivery[J]. Drug Dev Ind Pharm,1997,23(9): 893-913
[8]齐美玲,王鹏,吴德孜.替硝唑结肠给药系统的研制[J].中国医药工业杂志,2003, 34(34):172
[9] Muraokea M,Hu Z,Shimokawa T,et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers.J Controlled Release,1998,52(1/2):119-129
[10] Muraokea M,Kimura G,Zhaopeng H,et al. Ulcerative colitis-colon delivery of 5-aminosalicylic carriers to the inflamed colonic mucosa [J]. Nippon Rinsho,1998, 56(3):788
[11] Zoe W,John F,David A,et al. Studies on amidated pectins as potential carriers in colonic drug delivery [J]. J Pharm Pharmacol,1997,49(4):622-625
[12] KaKoulide EP,Smart JD,Tsibauklis J.Azocrosslinked poly for colonic delivery and adhesion specificity. In vitro degradation and preliminary ex vivo bioadhesion studies [J]. J Controlled Release,1998,54(2):95-109
[13] Mooter GVD,Maris B,Samyn C,et al .Use of azo-polymers for colon-specific drug delivery [J]. J Pharm Sci,1997,86(12):1312-1318
[14] Wei NH ,Lu B,Preparation,morphology and in vitro release of chitosan coated liposomes of fluorouracil for colon targeting [J]. Acta Pharm Sci(药学学报),2003,38(1):53-56
[15]张瑜,侯世祥,陈钢,等.魔芋胶为载体的结肠定位给药系统体外释放介质研究[J].中国药学杂志,2006,4(41):604-607
[16] Ishibashi T,Pitcairn GR,Yoshino H,et al. Dcintigraphic evaluation of a new capsule-type colon specific drug delivery system in health volunteers.J Pharm Sci,1998,87(5):531
[17]李妍,李宏建,苏乐群等.4-氨基水杨酸钠结肠定位包衣片的制备与体外释放[J].中国医院药学杂志.2006,26(4):402-405
[18] NUGENT S G,KUMAR D,RAMPTON D S,et al.Intestinal luminal pH in inflammatory bowel disease:possible determinants and implications of therapy with aminosalicylates and other drugs[J].Gut,2001,48:571-577
[19]齐美玲,吴德政.结肠给药系统的设计及体内评价[J].中国临床药理杂志,2000, 16(2):150
[20] De Vos M,Verdievel H,Schoonjans R,et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparation[J].Gut,1992,33(10):1338.
[21] Frieri G,Pimpo MT,Palumbo G,et al.Anastomotic configuration and mucosal 5-aminosalicylic acid (5-ASA)concentrations in patients with Crohn‘s disease:a GISC study[J].Am j Gastroenteral,2000,95(6):1486.
[22]赵建,张钧寿,张瑛等.胰岛素微乳大鼠结肠给药的药效学研究[J].中国医科大学学报,2004,35(6):491
[23]刘洪英,郑小林,皮喜田,等.消化道定位药物释放技术及其在新药开发中的应用[J].中国药学杂志,2005,40(13):970
[1]葛贺,孙丕东.TNFα和SOD在溃疡性结肠炎发病中活性变化的实验探究[J].临床医学,2007,20(1):160-162
[2]陆立,周燕,王焕明等.肿瘤坏死因子与炎症性肠病[J].国外医学·消化系统疾病分册,1998,18(1):9-11
[3]杜学良,孙瑛,栾亮. TNF增加培养的内皮细胞与血小板粘附及其机制[J].中国病理生理杂志,1997,13(5):470-473
[4]王晓兰,吕和平,康跃军.肿瘤坏死因子α与炎症性肠病研究进展[J].洛阳医专学报,2002,20(3):264-265
[5]崔淑兰,祝斌,梁坚.溃疡性结肠炎病人血清中TNF–α的变化及其临床意义[J],当代医师杂志,1998,3(8):13-14
[6]锁堂,吴焕金,施达仁.白介素与溃疡性结肠炎[J].世界华人消化杂志,2006,14(4): 405-411
[7]古学文.溃疡性结肠炎患者血清中IL-2及sIL-2浓度变化的研究[J].临床和实验医学杂志,2003,2:153-158
[8]卢艺涛,高静,姚桂琴.溃疡性结肠炎患者相关细胞因子的实验性研究[J].现代预防医学,2005,32(7):735-736
[9]陈英群,马贵同.细胞因子与溃疡性结肠炎相关性研究进展[J].中国中西医结合消化杂志,2003,11(1 ):57-59
[10]李艳颖,陈津生.IL监测溃疡性结肠炎病情变化的研究进展[J].天津医科大学学报,2006,12(4):597-599
[11] Vainer B,Nielsen O,Hendel J,et al. Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease[J].Cytokine ,2000,12: 1531-1536
[12] Iwakura T ,Ishigame H .The IL-23/IL-17 axis in inflammation[J]. The Journal of Clinical Investigation,2006,116(5):1218-1222
[13]梁雄均,马泽,曾雅静.白介素4和17在溃疡性结肠炎发生发展中的作用[J].右江医学,2005,33(1):6-8
[14]张玲英,杨明清,游自立等.溃疡性结肠炎患者血清IL-18的变化及意义[J].现代中西医结合杂志,2002,11:586-589
[15]张维,赵志泉,刘平等.IL8、TNF–α在Hp感染中作用的研究[J].胃肠病学和肝病学杂志,2000,9:270-273
[16]刘井波,彭双清.脂质过氧化作用与线粒体损伤[J].中国预防医学杂志,2005,6(2): 167-170
[17] Koutrobakis I.E.et al.DIG[J].DIS.SCI.2004,49(9):1433-1437
[18]汤学民,李毓琦,何俊.尿中脂质过氧化物测定方法的探讨[J].广西医学,2003, 25(4):515-518
[19] Mulden TPJ ,et al. Decrease in two intestinal copper/zinc containing proteins with antioxidant function in inflammatory bowel disease[J]. Gut,1991,32 (10)∶1 146
[20] Menchen L,Colon AL,Madrigal JL,et al. Activity of inducible and neuronal nitric oxide synthases in colonic mucosa predicts progression of ulcerative colitis[J]. Am J Gastroenterol,2004,99 (9): 1756-1764.
[21]陈垦,汤斌,祝斌.溃疡性结肠炎患者血清一氧化氮检测及意义[J].中国医师杂志,2002,4(10):1073-1075
[22]魏艳静,卞红磊,武会珍.溃疡性结肠炎患者体内血小板功能状态研究[J].临床医学,2003,18(11):608-609
[23]施嫣红,黄培新,郭传勇.溃疡性结肠炎患者血小板功能的临床研究[J].同济大学学报(医学版),2006,27(2):48-50
[24]倪伟虹,杨英,陈隆典.活动性炎症性肠病与血小板参数的相关性及其临床意义[J].中国医师进修杂志(内科版),2006,29(12):25-27